Drugs / ARO-C3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05083364 | Feb 2022 → Sep 2025 | IgA glomerulonephritis, complement 3 glomerulopathy | Arrowhead Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-03-10 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy arrowheadpharma.com ↗ |
| 2023-02-28 | Arrowhead Pharmaceuticals | Results Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases arrowheadpharma.com ↗ |
| 2021-10-25 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases arrowheadpharma.com ↗
An application for approval of the clinical trial is being submitted to a local Ethics Committee and to the New Zealand Medicines and Medical Devices Safety Authority for review by the Standing Committee on Therapeutic Trials. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-03-10 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy arrowheadpharma.com ↗ |
| 2023-02-28 | Arrowhead Pharmaceuticals | Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases arrowheadpharma.com ↗ |
| 2022-02-18 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases arrowheadpharma.com ↗ |
| 2021-10-25 | Arrowhead Pharmaceuticals | Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases arrowheadpharma.com ↗ |
| 2021-10-12 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases arrowheadpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-C3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05083364 ↗ |
| Route | Subcutaneous | “3 doses of ARO-C3 by sc injection” NCT05083364 ↗ |